SCHEMBL6784154

SCHEMBL6784154

COC(=O)c1cc2c(cc1NC(=O)/C=C(/C)c1ccc3ccccc3c1)OCO2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.58
KMT2A Q03164 6/20 0.45
ALDH1A1 P00352 8/20 0.44
KDM4E B2RXH2 8/20 0.44
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 2/20 0.44
MEN1 O00255 4/20 0.44
TSHR P16473 4/20 0.44
GAA P10253 2/20 0.44
HPGD P15428 2/20 0.44
POLB P06746 2/20 0.44
ALOX12 P18054 1/20 0.43
TP53 P04637 2/20 0.42
MAPT P10636 2/20 0.42
HSD17B10 Q99714 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
MAPK1 P28482 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784877 0.89 TERT (0.70) TERTKMT2AALDH1A1KDM4ERAB9A
SCHEMBL6784696 0.88 TERT (0.67) TERTALDH1A1KDM4ERAB9ANPC1
SCHEMBL6781638 0.84 TERT (0.61) TERTKMT2AALDH1A1KDM4EGAA
SCHEMBL6782397 0.84 TERT (0.64) TERTKMT2AALDH1A1KDM4ETSHR
SCHEMBL6784219 0.83 TERT (0.78) TERTKMT2AALDH1A1KDM4ERAB9A
SCHEMBL6782055 0.82 TERT (0.65) TERTKMT2AALDH1A1KDM4ERAB9A
SCHEMBL6790307 0.81 TERT (0.58) TERTKMT2AALDH1A1KDM4ERAB9A
SCHEMBL6787843 0.81 TERT (0.61) TERTKMT2AALDH1A1KDM4EMEN1
SCHEMBL6786975 0.81 TERT (0.61) TERTALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL6784147 0.81 TERT (0.64) TERTKMT2AALDH1A1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885KMT2A 490/4885ALDH1A1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.